REGENXBIO Inc.RGNX
Price (close)
$7.24
Market cap
$477.9M
P/E
—
Revenue (TTM)
$174.5M
Net income
-$196.4M
Dividend yield
—
1-year total return
-22.6%
Net margin
-112.6%
Revenue growth
12.0%
Debt / equity
—
What REGENXBIO Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Net income | -$111.3M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
| Free cash flow | -$80.9M | $134.7M | -$238.2M | -$228.4M | -$175.6M | -$126.4M |
More on RGNX.
- REGENXBIO Inc. summary
- REGENXBIO Inc. financial statements
- REGENXBIO Inc. key metrics
- REGENXBIO Inc. health scores and style box
- REGENXBIO Inc. earnings
- REGENXBIO Inc. dividends
- REGENXBIO Inc. valuation
- REGENXBIO Inc. ownership and insiders
- REGENXBIO Inc. peers
Figures from REGENXBIO Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.